Loading stock data…
LSTA
$3.13+0.01 (+0.32%)
Market ClosedLast close May 1
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lisata Therapeutics, Inc. in the Healthcare sector is trading at $3.13. The stock is currently 38% below its 52-week high of $5.07, remaining 2.3% above its 200-day moving average. Technical signals show oversold RSI of 21 and bearish MACD signal, explaining why LSTA maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 21) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.13
Potential Upside
5%
Whystock Fair Value$3.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.89M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-111.65%
Volume
Today's trading volume
7,851
Recent News
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other serious diseases, announced that it has agreed to be acquired by privately held Kuva Labs. Under the terms of a definitive agreement, Kuva will...
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching
Major stock indexes in the United States recently rebounded, closing sharply higher after a period of volatility driven by geopolitical tensions and economic policy shifts. In this context, investors are increasingly looking for opportunities that balance affordability with growth potential. While the term 'penny stocks' may seem outdated, it still refers to smaller or emerging companies that can offer significant value when backed by strong financials. In this article, we explore three penny...
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook
Why the Lisata Therapeutics Price Target Just Changed Lisata Therapeutics just saw its price target revised, and that shift reflects a fresh read on the company’s current position and risks rather than a simple reaction to short term share moves. With new commentary reshaping how some analysts frame the story, the focus is now less on where the stock has been and more on how its narrative is being reassessed. Stay with this article to see how you can keep on top of future shifts in that...
Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ...
Lisata Therapeutics Inc (LSTA) reports positive development milestones and strategic partnerships, while navigating funding hurdles for future trials.
Lisata Therapeutics Partners with Catalent on ADC Technology
By Karen Roman Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it started a global product license agreement with Catalent, Inc., enabling the latter to include Lisata’s certepetide into antibody-drug conjugates (ADCs) developed using Catalent’s SMARTag technology platform. The partnership is a validation of certepetide’s versatility and positions Lisata’s technology within a leading ADC platform, the company […]